176 related articles for article (PubMed ID: 30179260)
1. Clinical Pharmacokinetic and Pharmacodynamic Overview of Nilotinib, a Selective Tyrosine Kinase Inhibitor.
Tian X; Zhang H; Heimbach T; He H; Buchbinder A; Aghoghovbia M; Hourcade-Potelleret F
J Clin Pharmacol; 2018 Dec; 58(12):1533-1540. PubMed ID: 30179260
[TBL] [Abstract][Full Text] [Related]
2. Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia.
Deremer DL; Ustun C; Natarajan K
Clin Ther; 2008 Nov; 30(11):1956-75. PubMed ID: 19108785
[TBL] [Abstract][Full Text] [Related]
3. Nilotinib for imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase, accelerated phase, or blast crisis: a single- and multiple-dose, open-label pharmacokinetic study in Chinese patients.
Zhou L; Meng F; Yin O; Wang J; Wang Y; Wei Y; Hu P; Shen Z
Clin Ther; 2009 Jul; 31(7):1568-75. PubMed ID: 19695406
[TBL] [Abstract][Full Text] [Related]
4. Effects of nilotinib on single-dose warfarin pharmacokinetics and pharmacodynamics: a randomized, single-blind, two-period crossover study in healthy subjects.
Yin OQ; Gallagher N; Fischer D; Zhao L; Zhou W; Leroy E; Golor G; Schran H
Clin Drug Investig; 2011; 31(3):169-79. PubMed ID: 21184622
[TBL] [Abstract][Full Text] [Related]
5. Nilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemia.
Giles FJ; Yin OQ; Sallas WM; le Coutre PD; Woodman RC; Ottmann OG; Baccarani M; Kantarjian HM
Eur J Clin Pharmacol; 2013 Apr; 69(4):813-23. PubMed ID: 23052406
[TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles.
Di Gion P; Kanefendt F; Lindauer A; Scheffler M; Doroshyenko O; Fuhr U; Wolf J; Jaehde U
Clin Pharmacokinet; 2011 Sep; 50(9):551-603. PubMed ID: 21827214
[TBL] [Abstract][Full Text] [Related]
7. Clinical pharmacokinetics of the BCR-ABL tyrosine kinase inhibitor nilotinib.
Tanaka C; Yin OQ; Sethuraman V; Smith T; Wang X; Grouss K; Kantarjian H; Giles F; Ottmann OG; Galitz L; Schran H
Clin Pharmacol Ther; 2010 Feb; 87(2):197-203. PubMed ID: 19924121
[TBL] [Abstract][Full Text] [Related]
8. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
Kantarjian HM; Hochhaus A; Saglio G; De Souza C; Flinn IW; Stenke L; Goh YT; Rosti G; Nakamae H; Gallagher NJ; Hoenekopp A; Blakesley RE; Larson RA; Hughes TP
Lancet Oncol; 2011 Sep; 12(9):841-51. PubMed ID: 21856226
[TBL] [Abstract][Full Text] [Related]
9. Effects of hepatic impairment on the pharmacokinetics of nilotinib: an open-label, single-dose, parallel-group study.
Yin OQ; Gallagher N; Tanaka C; Fisher D; Sethuraman V; Zhou W; Lin TH; Heuman D; Schran H
Clin Ther; 2009; 31 Pt 2():2459-69. PubMed ID: 20110053
[TBL] [Abstract][Full Text] [Related]
10. Drug evaluation: Nilotinib - a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of chronic myelocytic leukemia and beyond.
Jabbour E; Cortes J; Giles F; O'Brien S; Kantarijan H
IDrugs; 2007 Jul; 10(7):468-79. PubMed ID: 17642017
[TBL] [Abstract][Full Text] [Related]
11. Expanding Nilotinib Access in Clinical Trials (ENACT): an open-label, multicenter study of oral nilotinib in adult patients with imatinib-resistant or imatinib-intolerant Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase.
Nicolini FE; Turkina A; Shen ZX; Gallagher N; Jootar S; Powell BL; De Souza C; Zheng M; Szczudlo T; le Coutre P
Cancer; 2012 Jan; 118(1):118-26. PubMed ID: 21732337
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase.
Larson RA; Yin OQ; Hochhaus A; Saglio G; Clark RE; Nakamae H; Gallagher NJ; Demirhan E; Hughes TP; Kantarjian HM; le Coutre PD
Eur J Clin Pharmacol; 2012 May; 68(5):723-33. PubMed ID: 22207416
[TBL] [Abstract][Full Text] [Related]
13. Nilotinib.
Plosker GL; Robinson DM
Drugs; 2008; 68(4):449-59; discussion 460-1. PubMed ID: 18318563
[TBL] [Abstract][Full Text] [Related]
14. Nilotinib: a new tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia.
Jarkowski A; Sweeney RP
Pharmacotherapy; 2008 Nov; 28(11):1374-82. PubMed ID: 18956997
[TBL] [Abstract][Full Text] [Related]
15. Effects of rifampin and ketoconazole on the pharmacokinetics of nilotinib in healthy participants.
Tanaka C; Yin OQ; Smith T; Sethuraman V; Grouss K; Galitz L; Harrell R; Schran H
J Clin Pharmacol; 2011 Jan; 51(1):75-83. PubMed ID: 20702754
[TBL] [Abstract][Full Text] [Related]
16. Influence of UGT1A1 6, 27, and 28 polymorphisms on nilotinib-induced hyperbilirubinemia in Japanese patients with chronic myeloid leukemia.
Abumiya M; Takahashi N; Niioka T; Kameoka Y; Fujishima N; Tagawa H; Sawada K; Miura M
Drug Metab Pharmacokinet; 2014; 29(6):449-54. PubMed ID: 24898899
[TBL] [Abstract][Full Text] [Related]
17. Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
Hochhaus A; Saglio G; Larson RA; Kim DW; Etienne G; Rosti G; De Souza C; Kurokawa M; Kalaycio ME; Hoenekopp A; Fan X; Shou Y; Kantarjian HM; Hughes TP
Blood; 2013 May; 121(18):3703-8. PubMed ID: 23502220
[TBL] [Abstract][Full Text] [Related]
18. Nilotinib: in the first-line treatment of newly diagnosed Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase.
Garnock-Jones KP
Drugs; 2011 Aug; 71(12):1579-90. PubMed ID: 21861543
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study.
Hiwase D; Tan P; D'Rozario J; Taper J; Powell A; Irving I; Wright M; Branford S; Yeung DT; Anderson L; Gervasio O; Levetan C; Roberts W; Solterbeck A; Traficante R; Hughes T
Leuk Res; 2018 Apr; 67():109-115. PubMed ID: 29494928
[TBL] [Abstract][Full Text] [Related]
20. Nilotinib-induced liver injury: A case report.
Tan Y; Ye Y; Zhou X
Medicine (Baltimore); 2020 Sep; 99(36):e22061. PubMed ID: 32899072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
